| 101 |
15387370 | Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). | 2004 |
4 |
| 102 |
15613453 | Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. | 2004 Dec |
1 |
| 103 |
12586780 | Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. | 2003 Mar |
1 |
| 104 |
12960029 | The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. | 2003 Nov |
1 |
| 105 |
14531500 | Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. | 2003 Sep |
1 |
| 106 |
14559846 | Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. | 2003 Oct 1 |
2 |
| 107 |
14623525 | Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect. | 2003 Sep |
3 |
| 108 |
14649542 | Epidermal growth factor-responsive laryngeal squamous cancer cell line Hep2 is more sensitive than unresponsive CO-K3 one to quercetin and tamoxifen apoptotic effects. | 2003 |
1 |
| 109 |
11454885 | Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. | 2001 Jul 15 |
5 |
| 110 |
11559718 | Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. | 2001 Sep 15 |
3 |
| 111 |
11916224 | Prospects for combining hormonal and nonhormonal growth factor inhibition. | 2001 Dec |
2 |
| 112 |
10601607 | Regulation of estrogen receptor and epidermal growth factor receptor by tamoxifen under high and low estrogen environments in MCF-7 cells grown in athymic mice. | 2000 Jan-Feb |
1 |
| 113 |
11778232 | [Modulating effect of vitamin D3 in vitro on EGFR mRNA expression of human breast cancer cell lines]. | 2000 May |
1 |
| 114 |
10542936 | Expression of steroid receptors, Ki-67, and epidermal growth factor receptor in tamoxifen-treated endometrium. | 1999 Oct |
3 |
| 115 |
9815855 | Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. | 1997 Sep |
2 |
| 116 |
1616857 | Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line. | 1992 Jun |
1 |
| 117 |
2285594 | Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure. | 1990 Dec 20 |
2 |
| 118 |
2463445 | Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. | 1989 Jan 28 |
1 |
| 119 |
2576295 | Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. | 1989 |
3 |
| 120 |
3242819 | Regulation of human estrogen receptor gene, epidermal growth factor receptor gene, and oncogenes by estrogen and antiestrogen in MCF-7 breast cancer cells. | 1988 |
2 |